Who with suspected prostate cancer can benefit from Proclarix after multiparametric magnetic resonance imaging?. Issue 2 (June 2022)

• Record Type: Journal Article
• Authors: Morote, Juan; Campistol, Miriam; Regis, Lucas; Celma, Anna; de Torres, Inés; Semidey, Maria E.; Roche, Sarai; Mast, Richard; Santamaria, Anna; Planas, Jacques; Trilla, Enrique
• Is Part Of: International journal of biological markers. Volume 37:Issue 2(2022)
• Page Start: 218
• Page End: 223
• Publication Date: 2022-06
• Subjects: Clinically significant prostate cancer -- magnetic resonance imaging -- proclarix -- thrombospondin-1 -- cathepsin D -- prostate-specific antigen density; Cell receptors -- Periodicals; Histochemistry -- Periodicals; Tumor markers -- Periodicals; Tumor antigens -- Periodicals; 616.99407582
• DOI: 10.1177/03936155221081537
• Languages: English
• ISSNs: 0393-6155

Abstract

Proclarix is a new blood-based test to assess the likelihood of clinically significant prostate cancer (csPCa) defined as> 2 grade group. In this study, we analyzed whether Proclarix and PSA density (PSAD) could improve the selection of candidates for prostate biopsy after multiparametric magnetic resonance imaging (mpMRI). Proclarix and PSAD were assessed in 567 consecutive men with suspected PCa in whom pre-biopsy 3 Tesla mpMRI, scoring with Prostate Imaging-Report and Data System (PI-RADS) v.2, and guided and/or systematic biopsies were performed. Proclarix and PSAD thresholds having csPCa sensitivity over 90% were found at 10% and 0.07 ng/(mL*cm 3 ), respectively. Among 100 men with negative mpMRI (PI-RADS <3), csPCa was detected in 6 cases, which would have been undetected if systematic biopsies were avoided. However, Proclarix suggested performing a biopsy on 70% of men with negative mpMRI. In contrast, PSAD only detected 50% of csPCa and required 71% of prostate biopsies. In 169 men with PI-RADS 3, Proclarix avoided 21.3% of prostate biopsies and detected all 25 cases of csPCa, while PSAD avoided 26.3% of biopsies, but missed 16% of csPCa. In 190 men with PI-RADS 4 and 108 with PI-RADS 5, Proclarix avoided 12.1% and 5.6% of prostate biopsies, but missed 4.8% and 1% of csPCa, respectively. PSAD avoided 18.4% and 9.3% of biopsies, but missed 11.4% and 4.2% csPCa, respectively. We conclude that Proclarix outperformed PSAD in the selection of candidates for prostate biopsy, especially in men with PI-RADS< 3.